UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Treatment of intermediate-stage hepatocellular carcinoma

Nature reviews. Clinical oncology, 2014-09, Vol.11 (9), p.525-535

2014

Volltextzugriff (PDF)

Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere

The lancet oncology, 2020-04, Vol.21 (4), p.479-481

2020

Volltextzugriff (PDF)

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond

Cancer treatment reviews, 2018-07, Vol.68, p.16-24

2018

Volltextzugriff (PDF)

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

Cancer, 2012-01, Vol.118 (1), p.147-156

2012

Volltextzugriff (PDF)

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

Journal of clinical oncology, 2013-01, Vol.31 (1), p.23-29

2013

Volltextzugriff (PDF)

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

The New England journal of medicine, 2011-02, Vol.364 (6), p.501-513

2011

Volltextzugriff (PDF)

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3509-3516

2013

Volltextzugriff (PDF)

Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer

JAMA network open, 2021-06, Vol.4 (6), p.e2113739-e2113739

2021

Volltextzugriff (PDF)

Objective Response by mRECIST as a Predictor and Potential Surrogate End Point of Overall Survival in Advanced HCC

Journal of hepatology, 2017-06, Vol.66 (6), p.1166-1172

2017

Volltextzugriff (PDF)

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Journal of clinical oncology, 2013-10, Vol.31 (28), p.3517-3524

2013

Volltextzugriff (PDF)

Prognostication of HCC under sorafenib: Is it always possible?

Liver international, 2020-05, Vol.40 (5), p.1241-1243

2020

Volltextzugriff (PDF)

High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation

The Journal of nuclear medicine (1978), 2014-11, Vol.55 (11), p.1786-1790

2014

Volltextzugriff (PDF)

Prognostic value of PDL1 expression in pancreatic cancer

Oncotarget, 2016-11, Vol.7 (44), p.71198-71210

2016

Volltextzugriff (PDF)

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study

British journal of cancer, 2020-08, Vol.123 (4), p.518-524

2020

Volltextzugriff (PDF)

Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer

Journal of clinical oncology, 2008-05, Vol.26 (13), p.2099-2105

2008

Volltextzugriff (PDF)

How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective

Liver cancer (Basel ), 2014-05, Vol.3 (2), p.119-124

2014

Volltextzugriff (PDF)

A 25-gene classifier predicts overall survival in resectable pancreatic cancer

BMC medicine, 2017-09, Vol.15 (1), p.170-170, Article 170

2017

Volltextzugriff (PDF)

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Journal of hepatology, 2018-07, Vol.69 (1), p.182-236

2018

Volltextzugriff (PDF)

Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence

Cancer treatment reviews, 2019-01, Vol.72, p.28-36

2019

Volltextzugriff (PDF)

New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations

Cancers, 2022-11, Vol.14 (23), p.5868

2022

Volltextzugriff (PDF)

An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma

Expert opinion on pharmacotherapy, 2017-09, Vol.18 (14), p.1467-1476

2017

Volltextzugriff (PDF)

Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper

Cancers, 2022-02, Vol.14 (5), p.1156

2022

Volltextzugriff (PDF)

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)

BMC cancer, 2011-08, Vol.11 (1), p.346-346, Article 346

2011

Volltextzugriff (PDF)

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses

Journal of hepatology, 2012-05, Vol.56 (5), p.1080-1088

2012

Volltextzugriff (PDF)

1 – 25 von 445

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(383)
Mit Volltextzugriff
(388)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Treatment of intermediate-stage hepatocellular carcinoma

Systemic treatment of hepatocellular carcinoma: standard of care in China and elsewhere

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma

Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

Prevalence of Proton Pump Inhibitor Use Among Patients With Cancer

Objective Response by mRECIST as a Predictor and Potential Surrogate End Point of Overall Survival in Advanced HCC

Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

Prognostication of HCC under sorafenib: Is it always possible?

High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation

Prognostic value of PDL1 expression in pancreatic cancer

Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study

Individual Fluorouracil Dose Adjustment Based on Pharmacokinetic Follow-Up Compared With Conventional Dosage: Results of a Multicenter Randomized Trial of Patients With Metastatic Colorectal Cancer

How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective

A 25-gene classifier predicts overall survival in resectable pancreatic cancer

EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence

New Challenges Facing Systemic Therapies of Advanced HCC in the Era of Different First-Line Immunotherapy-Based Combinations

An in-depth review of chemical angiogenesis inhibitors for treating hepatocellular carcinoma

Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper

Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)

Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses

Suchergebnisse filtern